AbbVie Inc. logo

AbbVie Inc. (ABBV)

Market Closed
9 Dec, 20:00
NYSE NYSE
$
222. 99
-0.13
-0.06%
$
402.32B Market Cap
42.2 P/E Ratio
6.2% Div Yield
2,667,089 Volume
10.28 Eps
$ 223.12
Previous Close
Day Range
220.23 224.8
Year Range
164.39 244.81
Want to track ABBV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 50 days
High Yields And Low Multiples - 3 Of My Favorite Dividend Stocks To Buy Right Now

High Yields And Low Multiples - 3 Of My Favorite Dividend Stocks To Buy Right Now

JPMorgan CEO Jamie Dimon expressed concern about inflation and predicts higher interest rates for longer than expected. He highlighted secular drivers such as the energy transition, geopolitical issues, infrastructure spending, and large deficits/debt levels. The favorable period for inflation in developed nations from 2009 to 2021 is likely over.

Seekingalpha | 1 year ago
3 Biotech Stocks to Buy on the Dip: May 2024

3 Biotech Stocks to Buy on the Dip: May 2024

Biotech is one of the most exciting industries to invest in right now. Companies have drugs on the market worth billions and continue to strive to produce the newest and best treatments in modern medicine.

Investorplace | 1 year ago
Why AbbVie (ABBV) is a Top Value Stock for the Long-Term

Why AbbVie (ABBV) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 1 year ago
A Must-Own Stock for Any Portfolio

A Must-Own Stock for Any Portfolio

This company offers growth, high yield, and dividend growth.

Fool | 1 year ago
2 Billion More Reasons to Buy AbbVie Stock

2 Billion More Reasons to Buy AbbVie Stock

AbbVie is bolstering its psychiatry pipeline with an acquisition. The biotech it's acquiring is developing psychedelic-adjacent drugs.

Fool | 1 year ago
3 S&P 500 Stocks That Have Proven Themselves Recession-Proof

3 S&P 500 Stocks That Have Proven Themselves Recession-Proof

Since 1928, there have been 25 bear markets, or declines in the S&P 500 of 20% or more, according to Yardeni Research. Market corrections have been far more common.

Investorplace | 1 year ago
1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?

1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?

AbbVie's lead drug Humira lost its patent-protected market exclusivity in the U.S. last year. Despite shrinking Humira revenues, AbbVie's first-quarter sales grew thanks to more recently launched blockbusters.

Fool | 1 year ago
7 Value Stocks to Buy and Hold for a Decade of Dominance

7 Value Stocks to Buy and Hold for a Decade of Dominance

Finding equities with the potential for steady, long-term development is crucial. These seven prospects span a variety of industries and offer solid arguments for long-term investment.

Investorplace | 1 year ago
Are You Looking for a High-Growth Dividend Stock?

Are You Looking for a High-Growth Dividend Stock?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?

Zacks | 1 year ago